ClonaCell™-HY AOF膨胀培养基

含有次黄嘌呤和胸腺嘧啶的杂交瘤扩增培养基(无动物源性)

产品号 #(选择产品)

产品号 #03835_C

含有次黄嘌呤和胸腺嘧啶的杂交瘤扩增培养基(无动物源性)

产品优势

  • 动物origin-free
  • 血清的缺失减少了培养基中表现的可变性
  • 简化下游克隆筛选和抗体纯化(无血清源性IgG)

概述

ClonaCell™-HY AOF扩增培养基是一种无动物源(AOF)和无血清的液体培养基,经次黄嘌呤、氨基蝶呤、胸腺嘧啶(HAT)选择后,优化用于杂杂瘤扩增。该培养基含有次黄嘌呤和胸腺嘧啶(HT),用于使杂交瘤在选择过程中脱离氨基蝶呤。ClonaCell™-HY AOF扩增培养基促进杂杂瘤的强大扩增,从含血清培养基到无血清培养基的适应,并稳定杂杂瘤细胞系的活力和抗体生产力。大多数杂交瘤可以直接从含血清培养基切换到ClonaCell™-HY AOF扩增培养基,无需适应步骤。这种培养基中不含血清,便于检测和纯化所需的杂交瘤源性抗体,而不受血清源性免疫球蛋白的干扰。

该培养基已被证实可用于小鼠和大鼠杂交瘤,适用于小鼠骨髓瘤(如Sp2/0)、大鼠骨髓瘤(如YB2/0)和人类骨髓瘤(如U266)的扩增。在大多数情况下,冷冻保存的杂交瘤可以直接解冻到ClonaCell™-HY AOF扩增培养基中,同时保持高水平的活力。该培养基可作为无血清的ClonaCell™-HY medium a(目录#03801)或ClonaCell™-HY medium E(目录#03805)的替代品。在制造该介质或其成分时,不使用动物或人类来源的材料,至少达到二级制造水平。

该培养基已验证适用于小鼠和大鼠杂交瘤,并支持小鼠骨髓瘤(如Sp2/0)、大鼠骨髓瘤(如YB2/0)及人骨髓瘤(如U266)的扩增。在大多数情况下,冻存的杂交瘤可直接解冻至ClonaCell™-HY AOF扩增培养基,同时保持高存活率。本培养基可作为ClonaCell™-HY Medium A(产品号 #03801)或ClonaCell™-HY Medium E(产品号 #03805)的无血清替代方案。该培养基及其成分的生产中,至少在次级原材料水平不含任何动物源或人源成分。

Contains
• Hypoxanthine and thymidine (HT)
• Gentamicin
• Phenol red
• L-Glutamine and other supplements
• Other ingredients, including recombinant proteins
 
Subtype
Specialized Media
 
Cell Type
Hybridomas
 
Species
Human, Mouse, Rat
 
Application
Cell Culture
 
Brand
ClonaCell
 
Area of Interest
Antibody Development, Cell Line Development, Hybridoma Generation
 
Formulation Category
Serum-Free
 

Data Figures

Cloning Efficiencies for Three Hybridoma Cell Lines Subcloned in Serum-containing and Serun-free Cell Culture Media

Figure 1. Cloning Efficiencies for Three Hybridoma Cell Lines Subcloned in Serum-containing and Serum-free Cell Culture Media

The hybridoma lines were adapted to growth in each medium and subcloned by limiting dilution (n = 1 - 5). After incubation for 10 days (37°C, 5% CO2), the plates were analyzed with a Cell Metric™ instrument (Solentim). The plating efficiency was estimated by Poisson statistics using the ELDA method described by Hu & Smith, 2009 (J Immunol Meth, 347: 70-78). ACF = animal component-free. Data is expressed as mean + 1 SD.

Graph comparing growth of hybridoma cell line expanded in commercially available serum-containing and serum-free hybridoma cell culture media.

Figure 2. Expansion of an Established Hybridoma Cell Line in Several Commercially-Available Serum-Containing and Serum-Free Hybridoma Cell Culture Media

The hybridoma line was adapted to growth in 13 different cell culture media: ClonaCellTM-HY AOF Expansion Medium (animal origin-free), DMEM + 10% FBS or ClonaCellTM-HY Medium E (serum-containing), Medium 1 (serum-free with serum-derived proteins), Medium 2 – 4 (serum-free), Medium 5 (animal component-free), Medium 7, 9 (protein-free), and Medium 11 – 13 (chemically-defined). They were then seeded in triplicate in 24-well tissue culture plates at 5 x 103 cells/mL. The cultures were incubated at 37°C (5% CO2 atmosphere) and the viable cell density was measured on days 3 – 7. Data is expressed as mean ± 1SD.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
03835
Lot #
All
Language
English
Document Type
Technical Manual
Catalog #
03835
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
03835
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

更多信息

更多信息
Species Human, Mouse, Rat
Contains • Hypoxanthine and thymidine (HT) • Gentamicin • Phenol red • L-Glutamine and other supplements • Other ingredients, including recombinant proteins
Formulation Category Serum-Free
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。